In support of this finding, a Korean cohort study revealed that SGLT2 inhibitors reduce dementia and PD risk in type 2 diabetes patients, underscoring the neuroprotective potential of improving insulin resistance (Kim et al., 2024). The gene discussed is SLC5A2; the disease is dementia.